Stay updated on Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page.

Latest updates to the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check18 days agoChange DetectedThe web page has been updated to announce a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check61 days agoChange DetectedThe page has undergone significant content removal, particularly regarding a clinical study on Stage III NSCLC treatments, including detailed eligibility criteria and study protocols. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference32%
- Check68 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check111 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page.